U.S. FDA Accepts PharmaEssentia’s Application for Ropeginterferon Alfa-2b to Treat Polythycemia Vera
U.S. team begins commercial preparations for novel pegylated interferon with appointment of General Manager Meredith Manning BURLINGTON, Mass.–(BUSINESS WIRE)–PharmaEssentia Corporation…